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The development of safe and effective drugs relies
on the discovery of selective ligands. Serotonin
(5-hydroxytryptamine [5-HT]) G protein-coupled re-
ceptors are therapeutic targets for CNS disorders
but are also associated with adverse drug effects.
The determination of crystal structures for the 5-
HT1B and 5-HT2B receptors provided an opportunity
to identify subtype selective ligands using struc-
ture-based methods. From docking screens of 1.3
million compounds, 22 molecules were predicted
to be selective for the 5-HT1B receptor over the
5-HT2B subtype, a requirement for safe serotonergic
drugs. Nine compounds were experimentally verified
as 5-HT1B-selective ligands, with up to 300-fold
higher affinities for this subtype. Three of the ligands
were agonists of the G protein pathway. Analysis of
state-of-the-art homology models of the two 5-HT
receptors revealed that the crystal structures were
critical for predicting selective ligands. Our results
demonstrate that structure-based screening can
guide the discovery of ligands with specific selec-
tivity profiles.
INTRODUCTION
G protein-coupled receptors (GPCRs) are the largest class of
membrane proteins and are responsible for extracellular recog-
nition of a wide range of molecules, spanning from neurotrans-
mitters to hormones and peptides (Katritch et al., 2013). These
receptors play crucial roles in many physiological processes
and have received considerable attention from the pharmaceu-
tical industry. Close to 30% of all drugs approved by the U.S.
Food and Drug Administration target GPCRs (Overington et al.,
2006). A large fraction of these are similar to endogenous mole-
cules, which reflects that drug discovery efforts have typically
been carried out via ligand-oriented medicinal chemistry ap-
proaches (Newman and Cragg, 2007). Although the design of
drugs based on natural ligands has been successful, it is often
associated with difficulties to achieve selectivity. This is particu-1140 Structure 22, 1140–1151, August 5, 2014 ª2014 Elsevier Ltd Allarly problematic for membrane receptors, as many subtypes
recognize the same molecule, for example, the family of 13
serotonin (5-hydroxytryptamine [5-HT], compound 1) receptors
(Hannon and Hoyer, 2008; Hoyer et al., 1994). As off-target inter-
actions are major causes of adverse drug effects and failures
in clinical trials, the identification of selective ligands is a critical
aspect of the drug discovery process (Giacomini et al., 2007).
As atomic resolution structures were not available for any
pharmaceutically relevant GPCR until 2007, the structural basis
for drug selectivity profiles was largely unknown at the time
of development. The 5-HT receptors are targets of several
marketed drugs for CNS diseases. Triptans are a successful
class of serotonergic drugs that are widely used to treat migraine
(The Sumatriptan Cluster Headache Study Group, 1991). The
triptans share the tryptamine substructure of the endogenous
ligand serotonin (compound 1) with substitutions on the aromatic
ring that render them to bind selectively to the 5-HT1B/D subtypes
(Figure 1). However, serotonergic drugs have also been with-
drawn from the market because of off-target interactions. The
antiobesity drug combination ‘‘fen-phen’’ was retracted after
the discovery that one of its components caused fatal heart
problems because of interactions with the 5-HT2B receptor
(Berger et al., 2009). A major step toward understanding seroto-
nergic drug selectivity was the recent determination of high-res-
olution crystal structures for the human 5-HT1B and 5-HT2B re-
ceptors (Liu et al., 2013; Wang et al., 2013). These structures
revealed the molecular basis of ligand binding and the signaling
profile of the co-crystallized agonist ergotamine (compound 2)
(Wacker et al., 2013). Furthermore, comparison of the receptor
structures revealed that differences in transmembrane helix
(TM) 5 were responsible for the subtype selectivity of triptans
(Figure 1) (Wang et al., 2013).
The revolution in GPCR structural biology has enabled the
use of structure-based approaches in ligand discovery for
several pharmaceutically relevant receptors (Kooistra et al.,
2013; Shoichet and Kobilka, 2012). The molecular docking
method can be used to computationally screen large chemical
databases for small molecules that complement a receptor-
binding site. Docking screens against GPCR crystal structures
have been characterized by high hit rates and the discovery of
novel lead compounds for several receptor families (Carlsson
et al., 2010, 2011; de Graaf et al., 2011; Katritch et al., 2010;
Kolb et al., 2009; Kruse et al., 2013; Mysinger et al., 2012;
Negri et al., 2013). For example, in the docking screens byl rights reserved
Figure 1. Structures, Binding Modes, and Selectivity for 5-HT1B
Receptor Ligands
(A) Crystallographic structures of the 5-HT1B and 5-HT2B receptors in complex
with ergotamine.
(B) Structural features responsible for 5-HT1B selectivity and the chemical
structures of three representative 5-HT1B agonists. The tryptamine substruc-
ture of the ligands is marked in red.
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Discovery of Selective 5-HT1B Receptor Ligandsde Graaf et al. (2011) and Lane et al. (2013) against H1 hista-
mine and D3 dopamine receptor crystal structures, remarkable
hit rates of 73% and 56%, respectively, were achieved. The
crystal structures have also served as templates for generating
homology models of GPCRs, which have been used success-
fully in prospective screening (Bissantz et al., 2005; Carlsson
et al., 2011; Cavasotto et al., 2008; Evers and Klabunde,
2005; Kolb et al., 2012; Langmead et al., 2012; Sirci et al.,
2012; Varady et al., 2003). However, discovered ligands have
often not been selective for the target subtype, which is notStructure 22, 1140surprising considering the subtle differences in the orthosteric
sites of many GPCR families. To test if crystal structures could
guide the discovery of subtype selective 5-HT1B modulators,
we carried out molecular docking screens of 1.3 million chem-
icals against the orthosteric sites of the 5-HT1B and 5-HT2B re-
ceptors. Twenty-two previously uncharacterized compounds
were evaluated experimentally, which led to the discovery of
nine 5-HT1B ligands that were selective for this receptor over
the 5-HT2B subtype. We also investigated the ability of homol-
ogy models to identify selective ligands on the basis of the re-
sults of a recent community-wide assessment (GPCR Dock
2013) to predict the 5-HT1B and 5-HT2B receptor crystal struc-
tures (Kufareva et al., 2014; in this issue of Structure). Although
our models were among the most accurate in the assessment,
they did not capture the most important features responsible
for subtype selectivity. Our results demonstrate the utility of
atomic resolution structures in ligand discovery and suggest
that the structural determination of closely related receptors
will be key for rational design of selective drugs.
RESULTS
Docking Screen for 5-HT1B-Selective Ligands
Access to high-resolution crystal structures of the 5-HT1B and
5-HT2B receptors provided an excellent opportunity to identify
subtype selective ligands via structure-based screening. To
this end, the crystallographic coordinates of the 5-HT1B and
5-HT2B receptors (Wang et al., 2013) were prepared for molecu-
lar docking screening in DOCK3.6 (Irwin et al., 2009). A library
of 1.3 million commercially available molecules from the ZINC
database (Irwin et al., 2012) were docked to the orthosteric sites
of both receptors. Up to 1,000 conformations for each com-
pound were sampled in (on average) 12,000 and 30,000 orienta-
tions in the 5-HT1B and 5-HT2B receptor binding sites, respec-
tively. Binding energies were predicted using a physics-based
scoring function (Mysinger and Shoichet, 2010). After the library
had been screened, all molecules were given database ranks
for the 5-HT1B and 5-HT2B receptor subtypes on the basis of
their scores. To identify selective ligands, only molecules that
were top ranked against the 5-HT1B receptor, but had sig-
nificantly lower ranks against the 5-HT2B subtype, were consid-
ered. Encouragingly, we found that several 5-HT1B-selective
triptans were among the top-ranked molecules for the 5-HT1B
receptor but had significantly lower ranks against the 5-HT2B
subtype, which was consistent with their selectivity profiles
(Wang et al., 2013).
The results of the docking screens against the 5-HT1B
and 5-HT2B receptors were filtered in several steps to identify
5-HT1B-selective ligands. The 4,000 top-ranked molecules for
the 5-HT1B receptor were first analyzed. A large fraction of these
had relatively small differences in rank between subtypes, which
reflected the sequence and structure conservation among the
binding sites of serotonin receptors. Differences in rank of less
than 50,000 were occasionally found to be sensitive to changes
in docking parameters, which excluded 65% of the 4,000 top-
ranked compounds. For the remaining 35%, the 500 compounds
with the worst scores against the antitarget (the 5-HT2B receptor)
were selected. This resulted in a candidate set of compounds
with differences in ranks ranging from 100,000 to 1,200,000.–1151, August 5, 2014 ª2014 Elsevier Ltd All rights reserved 1141
Table 1. Experimental Data for 5-HT Ligands Discovered in the Molecular Docking Screening
2D Structure
Ki (mM)
a Fold Selectivity Docking Rankb
5-HT1B 5-HT2B 5-HT1B/5-HT2B 5-HT1B 5-HT2B
10 0.3 79.0 306x 778 347,168
6 0.7 >10 >15x 2,419 202,422
25 0.3 4.2 13x 2,350 1,236,394
23 0.8 >10 >12x 1,634 459,827
16 0.03 0.3 9x 723 987,562
13 0.2 1.3 6x 87 493,955
22 0.2 1.4 6x 734 831,325
24 0.4 2.0 6x 2,035 1,044,009
12 1.8 >10 >5x 1,274 623,822
20 4.9 2.3 0.5x 256 214,721
(Continued on next page)
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Table 1. Continued
2D Structure
Ki (mM)
a Fold Selectivity Docking Rankb
5-HT1B 5-HT2B 5-HT1B/5-HT2B 5-HT1B 5-HT2B
18 >10 3.3 <0.3x 3,334 935,653
8 >10 2.9 <0.3x 918 140,007
4 1.3 0.1 0.08x 726 472,925
See also Figure S2 and Table S2.
aCalculated from three independent measurements. The uncertainty in each measured Ki is below a ±30% deviation.
bRank after a docking screen of 1.3 million leadlike compounds from the ZINC database.
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Discovery of Selective 5-HT1B Receptor LigandsThese molecules were deeply buried in the orthosteric site of
the 5-HT1B receptor structure and overlapped with the ergoline
core of the cocrystallized agonist ergotamine. The predicted
binding poses for the same molecules in the 5-HT2B receptor
structure were typically displaced from the orthosteric site and
lacked interactions with TM5 or TM6. Themore enclosed binding
site of the 5-HT2B subtype, resulting from a main chain kink
and bulkier side chains in TM5, precluded accommodation of
molecules that extended toward this region in the 5-HT1B struc-
ture (Figure 1; Figure S1 available online). Compound selection
was based on complementarity to the 5-HT1B receptor binding
site and absence of the same interactions with the 5-HT2B recep-
tor structure. Focus was also put on energy terms that were not
explicitly taken into account by the scoring function, for example,
ligand internal energy and receptor desolvation, as described
previously (Kolb et al., 2009; Kruse et al., 2013; Mysinger et al.,
2012; Negri et al., 2013; Weiss et al., 2013). Based on these con-
siderations, 22 compounds were selected for experimental
testing and purchased from commercial vendors (Table S1 and
Figure S1). To our knowledge, none of these compounds had
previously been evaluated experimentally against the 5-HT1B
or 5-HT2B receptors.
Binding Assays and Subtype Selectivity
The 22 predicted ligands were evaluated in radioligand binding
assays for both the 5-HT1B and 5-HT2B receptors. Thirteen
compounds showed significant radioligand displacement at
10 mM for at least one receptor (Table S1 and Figure S2). The
full dose-response curves showed that 11 compounds were
5-HT1B receptor binders with affinities better than 10 mM, which
corresponds to a docking hit rate of 50%. Eight compounds
were submicromolar ligands, and among these, compound 16
was the most potent (Ki = 29 nM). For the 5-HT2B receptor,Structure 22, 11408 compounds had Ki values better than 10 mM, but only two
of these were submicromolar binders. The molecular docking
and experimental data for the discovered ligands are shown in
Table 1.
In a second step, the selectivity profiles for the discovered
ligands were quantified using the ratios between their Ki values
at the two 5-HT receptor subtypes. Of the 11 5-HT1B ligands, 9
hadmore than 5-fold higher affinity for this subtype. Compounds
13, 22, 24, and 12 displayedmodest selectivities between 5- and
6-fold, whereas compound 16 was 9-fold selective. Compounds
6, 23, and 25 were submicromolar 5-HT1B ligands with
more than 10-fold selectivity for the 5-HT1B receptor over the 5-
HT2B subtype. Compound 10 was the most selective ligand with
a selectivity ratio of 306. Conversely, compounds 4, 8, 18, and
20 were more potent at the 5-HT2B receptor. Compound 4 was
12-fold antiselective, whereas compounds 18, 20, and 8 showed
weak (2- to 4-fold) preferences for the 5-HT2B subtype (Table 1).
The results of the docking screen are summarized in Figure 2.
Novelty and Structure-Activity Relationships
for Discovered Ligands
The chemical similarity of the discovered compounds to human
5-HT1B and 5-HT2B receptor ligands in the ChEMBL15 database
(Gaulton et al., 2012) was quantified by calculating the Tanimoto
similarity using ECFP4 fingerprints (Table S2). The Tanimoto
coefficients (Tc) reflected the topological similarity of our com-
pounds to previously characterized ligands. A Tc value equal to
1 would be obtained if there were an identical ligand in the
ChEMBL database, whereas low Tc values (<0.3) reflected
chemical dissimilarity to previously characterized ligands
(Wawer and Bajorath, 2010). The predicted binding modes for
the discovered ligands were also analyzed to rationalize the
structural basis for ligand selectivity.–1151, August 5, 2014 ª2014 Elsevier Ltd All rights reserved 1143
Figure 2. Schematic Overview of the Structure-Based Screen for 5-
HT1B-Selective Ligands
See also Figure S1 and Table S1.
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Discovery of Selective 5-HT1B Receptor LigandsCompound 16 displayed the highest affinity among the
discovered ligands (Ki = 29 nM) and represented a cluster of
compounds (including 13, 22, and 24) with resemblance to
serotonin and triptan drugs (compounds 1 and 3). This ligand
took advantage of the cavity volume that was occluded by
Met2185.39 in the 5-HT2B structure (Figure 3A) (superscripts
represent Ballesteros-Weinstein residue numbering for GPCRs;
Ballesteros and Weinstein, 1995). The compound retained core
features of classical serotonin receptor ligands, but as reflected
by its relatively low Tc value (0.33), the 6-position of the indole
ring was substituted with previously unexplored moieties. It is
also interesting to note that in contrast to ergotamine and the
triptans, compound 16 lacks a donor in the aromatic ring and
can hence not form a hydrogen bond to Thr1343.37.
The four most selective 5-HT1B ligands were also among the
most novel. Compounds 23, 6, 25, and 10 represented four
different 5-HT1B scaffolds with Tc values below 0.3, which is
typical for new chemotypes (Figures 3B–3E). The most novel
compound, 25 (Tc = 0.24), was 13-fold selective for the 5-HT1B
receptor and hydrogen bonded to the nonconserved residue
Ser3346.55 in its predicted binding mode (Figure 3D). For com-
pound 10 (Tc = 0.26), the 306-fold selectivity appeared to be
accomplished by the bulky pyridine-4-ylmethyl group that
formed a single hydrogen bond to Thr2095.39 (Figure 3E). To
test this prediction, we identified compound 26, an analog of
compound 10 that lacks the aforementioned aromatic moiety1144 Structure 22, 1140–1151, August 5, 2014 ª2014 Elsevier Ltd Al(Figure 4A). Docking poses of compound 26 showed good
complementarity with the binding sites of both receptors, sug-
gesting that it would not be selective. The lack of selectivity for
compound 26 was also confirmed by radioligand assays, sup-
porting the role of ligand interactions with TM5 as the origin of
5-HT1B selectivity for compound 10 (Table S3). Similarly, the
15-fold selectivity of compound 6 appeared to originate from
the methoxyphenyl group, which was predicted to form a
hydrogen bond to the hydroxyl group of Thr2095.39. To further
optimize this scaffold, commercially available analogs with other
substituents on the phenyl group were docked to the 5-HT1B and
5-HT2B receptor structures. Compound 27 only docked well into
the 5-HT1B receptor structure, and its hydroxymethyl group
was expected to form a stronger hydrogen bond to Thr2095.39
than the methoxy of compound 6. As predicted, compound
27 displayed 3-fold better affinity at the 5-HT1B receptor, and
selectivity was further improved to a 39-fold difference between
the two subtypes (Figure 4B; Table S3).
Functional Cyclic AMP Assays for Selective Ligands
With one notable exception (Weiss et al., 2013), all previous
docking screens have been carried out against GPCR structures
determined in complex with antagonists or inverse agonists. A
majority of the ligands discovered in these screens have also
been antagonists or inverse agonists, which suggests that an
efficacy bias may be encoded in the structures (Shoichet and
Kobilka, 2012). As the 5-HT1B receptor was cocrystallized with
ergotamine, which activates both G protein and b arrestin
signaling pathways, we wanted to assess if the discovered
ligands would also display agonist properties. To characterize
G protein-mediated signaling, the three compounds with the
highest 5-HT1B affinities among the five most selective ligands
were evaluated in assays measuring changes in intracellular
cyclic AMP (cAMP) levels (Figure 5). The tested ligands (com-
pounds 10, 16, and 25) represented three completely different
scaffolds, but all of themwere agonists of the G protein pathway.
Compounds 10 and 16 were full 5-HT1B agonists with half
maximal effective concentration (EC50) values equal to 1.6 and
0.6 mM. Compound 25 was a partial agonist that displayed
59% of the maximal response at 10 mM and had an EC50 of
0.8 mM (Table S4). Two ligands thus activated Gi protein-medi-
ated signaling as the cocrystallized ligand ergotamine (com-
pound 2), whereas the third was also an agonist that achieved
only partial 5-HT1B activation. The predicted binding modes for
the ligands were analyzed to rationalize these observed differ-
ences, which suggested that the levels of agonistic response
may originate from differences in interactions with TM5 and
TM6. The two full agonists, compounds 10 and 16, were
predicted to interact extensively with TM5 (Figures 3A and 3E)
and to form hydrogen bonds with Thr2095.39 (compounds 10
and 16) and Ser2115.42 (compound 16). The partial agonist
compound 25 did not extend as far toward the extracellular tip
of TM5 as the full agonists and instead established a polar con-
tact with Ser3346.55 (Figure 3D).
Prediction of 5-HT1B Selectivity from Homology Models
If structure-based screens could be carried out against a large
panel of receptors (e.g., all serotonin receptors or even the
entire receptorome), this would enable efficient identification ofl rights reserved
Figure 3. Novel and Selective 5-HT1B Ligands Discovered in the Docking Screen
Predicted binding modes of compounds 16 (A), 23 (B), 6 (C), 25 (D), and 10 (E) in the 5-HT1B receptor crystal structure (white cartoons) together with a super-
imposition of the structure of the 5-HT2B receptor (transparent blue cartoons). The conformation of ergotamine in the crystallographic structure of the 5-HT1B
receptor is shown in transparency in (A). Residues involved in polar interactions with the ligands are shown in sticks, as well as Met2185.39 of the 5-HT2B receptor.
Additionally, 2D structure comparisons to the closest annotated 5-HT1B ligand in the ChEMBL15 database are shown for compounds 25 and 10, together with
radioligand displacement curves for the 5-HT1B and 5-HT2B receptors. Point and vertical bars shown in binding curves represent themean and standard deviation
of three independent measurements, respectively. Reference compounds used in these assays were 5-carboxamidotryptamine (5-CT) and methysergide.
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Discovery of Selective 5-HT1B Receptor Ligandsselective leads. Unfortunately, considering the many challenges
in membrane protein crystallography, representative structures
for all relevant receptors will likely not be available in the foresee-
able future. Molecular docking screens against the receptorome
will instead have to rely on models for the large number of
GPCRs that have not yet been crystallized. However, it is not
clear if homology models have the accuracy required for predict-
ing selective ligands.
Before the release of the 5-HT1B and 5-HT2B receptor crystal
structures, a community-wide assessment (GPCR Dock 2013)
was organized to assess the accuracy of GPCR modeling,
particularly focusing on receptor-drug interactions (Kufareva
et al., 2011; Michino et al., 2009). The molecular modeling field
was challenged to submit atomic-level models of the 5-HT1B
and 5-HT2B receptors in complex with the agonist ergotamine
(compound 2). We, as well as the other 39 participating groups,
were allowed to submit five models for each of the 5-HT1B- and
5-HT2B-ergotamine complexes before the crystal structuresStructure 22, 1140were released. The results of the GPCR Dock 2013 assessment
are presented elsewhere (Kufareva et al., 2014), and only the per-
formance of our models, which were among the top ranked for
both receptors, is described here (Table S5). Our predictions of
the receptor-ligand complexes were determined to be the best
and fifth best solutions for the 5-HT1B and 5-HT2B subtypes,
respectively. More importantly, the models were also among
the three most accurate descriptions of the receptor binding
site for both subtypes. Access to predicted and crystallographic
structures of the 5-HT1B and 5-HT2B receptors allowed us to
analyze if state-of-the-art homology models had the accuracy
required for predicting selective ligands.
We first analyzed the orthosteric sites of the models and crys-
tal structures in detail. The most notable differences were the
conformation of TM5 and the side chain of residue position
5.39 (5-HT1B/Thr209 and 5-HT2B/Met218), which Xu and co-
workers identified to be responsible for the selectivity profile
of triptans based on the crystal structures and mutagenesis–1151, August 5, 2014 ª2014 Elsevier Ltd All rights reserved 1145
Figure 4. Structure-Activity Relationships for Analogs of Com-
pounds 10 and 6
Binding data (top) and predicted bindingmodes (bottom) for compounds 26 (A)
and 27 (B). Docking solutions for 26 and 27 in the 5-HT1B (white carbons) and
5-HT2B (cyan carbons) receptor crystal structures are shown in sticks. The
predicted binding modes of the parent compounds 10 and 6 in the 5-HT1B
receptor structure are shown in lines. See also Table S3.
Figure 5. Functional cAMP Assays for Discovered Ligands
Functional assays measuring the concentration-dependent production of
cAMP for compounds 16, 10, and 25. Points and vertical bars represent the
mean and standard deviation of three independent measurements, respec-
tively. Serotonin (compound 1) was used as reference compound. See also
Table S4.
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Discovery of Selective 5-HT1B Receptor Ligandsstudies (Wang et al., 2013). For the crystal structures, a 3 A˚
inward main chain shift of TM5 and the bulkier Met2185.39 side
chain of 5-HT2Bwere found to result in a narrower binding pocket
that could not accommodate the triptans as well as the open
cavity of the 5-HT1B subtype (Figure 6A). The backbone shift
was also captured by our models, but the corresponding dis-
tance was only 1.2 A˚ (Figure 6B). In addition, whereas the side
chain of Met2185.39 pointed straight into the binding site in the1146 Structure 22, 1140–1151, August 5, 2014 ª2014 Elsevier Ltd Al5-HT2B crystal structure, it was predicted to be in the interface
between TM5 and TM6 in our model. This led to a more open
model of the 5-HT2B receptor with a cavity shape that was similar
to that of the 5-HT1B crystal structure (and homology model)
(Figure 6A).
In a second step, we docked a series of five triptans to the
homology models and crystal structures (Figure S3). An exhaus-
tive search of ligand conformations was carried out for each
structure, and the complex with the lowest energy was analyzed.
In agreement with the analysis of drug binding to the serotonin
receptor structures (Wang et al., 2013), the indole rings of the
five triptans closely overlaid with that of ergotamine for the
5-HT1B receptor. We also found that the indole groups were dis-
placed and key polar interactions with Asp1353.32 and Thr1403.37
were missing for the 5-HT2B crystal structure, which agreed well
with the selectivity profile of triptans (Figure 6C; Figure S3). For
the homology models, none of the larger triptans (eletriptan
and donitriptan) could be docked to the orthosteric sites. This
was likely due to problems associated with the predicted struc-
ture of extracellular loop (EL) 2 and surrounding regions of
TM3 and TM5, which are difficult to model accurately
(de Graaf et al., 2008; Kufareva et al., 2011). The three smaller
triptans (sumatriptan, rizatriptan, and zolmitritpan) docked in
the same overall binding mode for both receptors, which closely
resembled that of ergotamine (Figure 6C; Figure S3). These bind-
ing poses did not agree with the selectivity profile for these
ligands and contrasted with the result obtained with the crystal
structures. As displacement from the orthosteric site of the
5-HT2B subtype was an important criterion for compound selec-
tion in the docking screen, none of these triptans would have
been predicted to be 5-HT1B selective based on docking to the
homology models. Furthermore, retrospective screening of the
1.3 million commercially available molecules against the models
showed that all the triptans were predicted to be antiselective on
the basis of their docking ranks. The same results were obtained
for the nine selective ligands discovered in our prospective
screen. Only compound 10 had better ranking for the 5-HT1B re-
ceptor, but as the predicted binding mode did not capture the
salt bridge to Asp1353.32, it would not have been selected for
experimental evaluation (Figure S3C).l rights reserved
Figure 6. Comparison of Crystal Structures and Homology Models of the 5-HT1B and 5-HT2B Receptors
(A) Conformations of TM5 in the crystal (left) and homology model (right) structures of the serotonin receptors.
(B) Top view of the inward kink of TM5 and rotamers of residues Thr2095.39 (5-HT1B) and Met218
5.39 (5-HT2B).
(C) Predicted binding modes of sumatriptan in the crystal structures (left) and homology models (right) of the 5-HT1B (white carbons) and 5-HT2B (cyan carbons)
receptors.
See also Figure S3 and Table S5.
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Three main results emerge from this study. The first is the suc-
cessful use of structure-based screening to discover selective
ligands of the 5-HT1B receptor, a drug target for migraine and
anxiety (Roth et al., 2000). Of 22 predicted ligands, 11 were
found to bind to the 5-HT1B receptor. Several ligands were
remarkably potent; 8 compounds had submicromolar affinities,
with the most active reaching a Ki value of 29 nM. The 50% hit
rate and high ligand affinities place this study among the most
successful structure-based screens against GPCRs to date
(Kooistra et al., 2013; Lane et al., 2013). The additional docking
screen against a crystal structure of an antitarget also enabled
us to bias the screen toward subtype selective ligands, a key
to successful drug development. The most selective ligand had
more than 300-fold higher affinity for the 5-HT1B receptor over
the 5-HT2B subtype. Our second finding was that the structures
not only guided the identification of selective ligands but also
biased the screen toward the discovery of canonical agonists.
Three 5-HT1B ligands from the screen activated G protein
signaling and could represent lead candidates against migraine.
Third, we took advantage of our participation in the GPCR DockStructure 22, 11402013 assessment to analyze the utility of computer-derived
models for prediction of ligand selectivity. Although our models
were among the most accurate, they lacked the structural fea-
tures that govern selectivity. Our results illuminate opportunities
enabled by the revolution in GPCR structural biology, but also
pinpoint limitations for the use of receptor models in structure-
based drug design.
Advances in crystallography for membrane proteins have
provided high-resolution structures for 15 GPCR families (Ka-
tritch et al., 2013; Venkatakrishnan et al., 2013). Several of these
have successfully been exploited in molecular docking screens,
demonstrating that structure-based approaches can contribute
to the discovery of novel scaffolds (Carlsson et al., 2010, 2011;
deGraaf et al., 2011; Katritch et al., 2010; Kolb et al., 2009; Kruse
et al., 2013; Mysinger et al., 2012; Negri et al., 2013). However,
opportunities to use structure-based methods to discover sub-
type selective ligands have been limited because of the lack of
structures representing several members of the same family.
Design of selective GPCR ligands has instead relied on ligand-
based approaches (Besnard et al., 2012; Keiser et al., 2009;
Rodrı´guez and Gutie´rrez-de-Tera´n, 2013) or homology models
(Katritch et al., 2011; Kolb et al., 2012; Selent et al., 2008). An–1151, August 5, 2014 ª2014 Elsevier Ltd All rights reserved 1147
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dopamine receptor ligands by Hopkins and colleagues (Besnard
et al., 2012). Homology models have also been used to analyze
drug selectivity profiles for aminergic GPCRs (Chien et al., 2010;
Selent et al., 2010; Selent et al., 2008). However, prospective
screening for selective GPCR ligands based on homology
models has had limited success (Kolb et al., 2012). To date,
structures of several human subtypes have been determined
only for the opioid, muscarinic, and serotonin receptors. These
structures confirmed that the difficulties to achieve subtype
selectivity were due to highly similar binding sites for receptors
within the same family. In an attempt to identify selective opioid
receptor (OR) ligands, 4.5 million compounds were screened
against the crystal structure of the k-OR receptor (Negri et al.,
2013). Selection of 22 compounds was based on the ability of
these to interact with nonconserved residues. The screen led
to the discovery of four weak ligands with affinities ranging
from 120 to 2,900 mM, of which two (9%) were more than 5-
fold selective. In another recent study, docking screens against
crystal structures of the M2 and M3 muscarinic receptors were
used to predict M3-selective ligands, a challenging endeavor
considering the subtle differences between the two binding
sites (Kruse et al., 2013). Of the 16 compounds that were ex-
perimentally evaluated, only 1 compound (6%) reached 5-fold
selectivity. As in that effort, we took advantage of docking
screens against both the target and antitarget structures and
selected compounds on the basis of differences in the predicted
binding modes and energies, but performed significantly more
ligand sampling. Nine 5-HT1B ligands, 41% of those experimen-
tally tested in this work, were more than 5-fold selective. In
particular, compounds 6, 10, and 25 are submicromolar leads
that are dissimilar to known ligands and display selectivities
from 13- to 300-fold. The predicted structure-activity relation-
ship for compound 10 was supported by the loss of selectivity
of a closely related analog. One scaffold was also further
optimized, both in terms of affinity and selectivity. These results
suggest that the crystal structures can also guide further devel-
opment of the discovered leads.
Although a majority of the assayed compounds could not
even be docked into the orthosteric site of the antitarget, a
few compounds were either non- or antiselective. Failures to
recognize these compounds as 5-HT2B ligands were likely
caused by the lack of receptor flexibility (induced fit) in the
molecular docking algorithm. The high docking hit rate for the
5-HT1B receptor suggests that it is sufficient to screen one
receptor structure to discover ligands. Conversely, to determine
that a molecule does not bind to a receptor, it would be
necessary to consider all relevant receptor conformations at
physiological conditions. This makes identification of selective
ligands from docking screens extremely difficult. Notwith-
standing these methodological challenges, several of the
discovered 5-HT1B ligands were selective. We hypothesize
that our successful discovery of selective ligands was made
possible via the multiple and conservative constraints put on
compound selection. The combination of large differences in
the predicted binding energy, strong ligand interactions with
nonconserved structural motifs, and displacement of the same
compound from the orthosteric site for the antitarget likely
enabled us to identify 5-HT1B-selective ligands.1148 Structure 22, 1140–1151, August 5, 2014 ª2014 Elsevier Ltd AlConsidering the emphasis put on selectivity in compound se-
lection, we did not anticipate that the crystal structures would
simultaneously bias the screen toward identifying ligands that
induce a similar functional response. To our surprise, three
ligands tested in functional assays were from partial to full ago-
nists of the G protein pathway, which was consistent with the
behavior of the cocrystallized ligand. Both experimental and
computational studies of the b-adrenergic receptors have sug-
gested that interactions with serine residues in TM5 are impor-
tant for activation (de Graaf and Rognan, 2008; Katritch et al.,
2009; Rasmussen et al., 2011; Warne et al., 2011; Weiss et al.,
2013). The predicted binding modes for the discovered agonists
also point to the importance of interactions with TM5 for full acti-
vation of the G protein pathway. The two full agonists showed
extensive contacts with TM5, whereas the partial agonist com-
pound 25 interacted primarily with TM6. In contrast to ergota-
mine, none of the discovered agonists formed a hydrogen
bond to Thr1343.37, which suggests that this interaction is not
critical for receptor activation. Experimental determination of b
arrestin signaling for these 5-HT1B agonists will also be required
to further characterize their functional behavior (Wacker et al.,
2013), which could contribute to deeper understanding of biased
signaling for the serotonin receptors.
Each new structure of a unique GPCR further extends the
number of receptors that can be accessed using homology
modeling techniques. At a threshold of 30% TM sequence
identity, models for more than 60% of all class A GPCRs can
currently be generated (Rodrı´guez and Gutie´rrez-de-Tera´n,
2013). Given access to a good template (>40% TM identity),
several studies suggest that GPCR homology models can suc-
cessfully be used in structure-based ligand discovery (Carlsson
et al., 2011; Kolb et al., 2012; Sirci et al., 2012). Blind prediction of
the 5-HT1B and 5-HT2B receptor crystal structures, and the sub-
sequent release of the experimental coordinates, enabled us to
assess if accurate models could also be used to discover selec-
tive leads. The high fidelity of our 5-HT1B receptor model was
encouraging and suggested that it would perform well in ligand
discovery, as previously demonstrated for the D3 dopamine
receptor (Carlsson et al., 2011). However, the 5-HT2B receptor
model failed to capture the most important structural differences
that were responsible for 5-HT1B selectivity. Main chain flexibility
and subtle differences in structure are challenging to predict
with current homology modeling techniques, which calls for the
development of novel strategies in this area. The incorporation
of ligand selectivity information in model building could be an
important first step, as recently shown for the adenosine recep-
tor family (Katritch et al., 2011).
Our results demonstrate that given high-resolution structures,
molecular docking screens against GPCRs are not limited to
ligand discovery but can also guide the design of modulators
with specific selectivity profiles. This suggests that structure-
based approaches will become a fruitful source of lead com-
pounds in drug discovery efforts for GPCRs.EXPERIMENTAL PROCEDURES
Molecular Docking Screens
Crystal structures of the 5-HT1B and 5-HT2B receptors (Protein Data Bank
[PDB] accession numbers 4IAR and 4IB4, respectively) (Wacker et al., 2013;l rights reserved
Structure
Discovery of Selective 5-HT1B Receptor LigandsWang et al., 2013) were prepared by removing all nonprotein atoms and the
BRIL insertion in intracellular loop three. Protonation states of ionizable resi-
dues were set to the most probable at pH 7. Flexible ligand docking calcula-
tions were performed with the program DOCK3.6 (Irwin et al., 2009; Lorber
and Shoichet, 2005; Mysinger and Shoichet, 2010). For each conformation
that passed a steric filter, the ligand-receptor binding energy was calculated
as the sum of the electrostatic and van der Waals interaction energies, cor-
rected for ligand desolvation. For the top scoring conformation of each
molecule, 100 steps of rigid-body energy minimization were also carried out.
The energy contributions were extracted from precalculated grids (Irwin
et al., 2009). Additionally, the side chain dipole moments of several residues
in the orthosteric site (5-HT1B receptor: Thr134
3.37, Thr2095.39, Ser2115.42,
Thr2125.43, and Ser3346.55; 5-HT2B receptor: Thr140
3.37, Ser2225.43, and
Asn3446.55) were increased as previously described (Carlsson et al., 2010;
Weiss et al., 2013). The desolvation penalty for a ligand conformation was
estimated from a precalculated grid of the transfer free energy of each docked
molecule from aqueous solution to a low-dielectric medium (Mysinger and
Shoichet, 2010). See Supplemental Experimental Procedures for details.
A library of commercially available molecules with one or more aliphatic
nitrogens, a characteristic feature of a majority of all serotonin receptor li-
gands, was extracted from the ZINC database (Irwin et al., 2012). The resulting
1.3 million compounds were docked to the orthosteric sites of both receptors.
Compounds with high internal energy motifs were removed automatically, as
described previously (Carlsson et al., 2011). To identify selective ligands, the
docking poses of 500 molecules that were ranked among the top 4,000 in
the screen against 5-HT1B receptor but had ranks worse than 100,000 against
5-HT2B were visually inspected. From these, a diverse set of 22molecules was
selected for experimental testing on the basis of the predicted binding modes,
availability for purchase, and chemical novelty.
Radioligand Binding Competition Assays
Tested compounds were purchased from the vendors Asinex, Chembridge,
Enamine, VitasM, and ChemDiv. Compound purity was confirmed by liquid
chromatography-mass spectrometry or nuclear magnetic resonance. Affinity
of the compounds at human 5-HT1B and 5-HT2B receptors was assessed in
radioligand binding competition studies using [3H]-GBR125743 and [3H]-
LSD for labeling, respectively. See Table S6 for details.
Functional cAMP Assays at Human 5-HT1B Receptors
G protein signaling mediated by 5-HT1B receptor activation was characterized
for compounds 10, 16, and 25 by measuring the modulation of intracellular
cAMP levels. Briefly, cells expressing human 5-HT1B receptors were seeded
in 96-well plates (15,000 cells/well) in the presence of 500 mM 3-isobutyl-1-
methylxanthine. Compounds were incubated at 25C for 10 min, and 1 mM
forskolin was then added and kept for an additional 5 min. Levels of cAMP
were quantified by using the cAMP HTRF dynamic kit (CisBio).
Experimental Data Analysis
Dose/response curves were fitted using GraphPad Prism version 2.1 (Graph-
Pad Software). The Cheng-Prussoff equation and nonlinear regression fitting
were used to calculate Ki and EC50 values, respectively.
Molecular Similarity Calculations
The software screenmd (ChemAxon, 2012) was used to calculate Tc values
using ECFP4 fingerprints. Known ligands of the human 5-HT1B and 5-HT2B re-
ceptors were retrieved from the ChEMBL database (Gaulton et al., 2012).
Generation of Homology Models
Computer-derived models of the 5-HT1B and 5-HT2B receptors bound to
ergotamine were generated prior to the release of their atomic coordinates.
Details of the methodology followed can be found elsewhere (Rodrı´guez et
al., 2014). Briefly, structures of the thermostabilized turkey b1 adrenergic re-
ceptor (Warne et al., 2012; Warne et al., 2011) were chosen as templates for
the transmembrane region and all loop segments except EL2, which was
modeled on the basis of the D3 dopamine receptor crystal structure (D3DR;
PDB accession number 3PBL) (Chien et al., 2010). For the 5-HT2B receptor,
additional alpha helix restraints were added for the extracellular tips of TM5
and TM7, and disulfide bridge restraints were introduced in EL2 and EL3 forStructure 22, 1140both targets. All homology models were generated using the program
MODELLER 9.11 (Sali and Blundell, 1993). Models were refined using a com-
bination of homology modeling and molecular docking with DOCK3.6. In each
round, 500models were generated and ranked by their discrete optimized pro-
tein energy (DOPE) scores (Shen and Sali, 2006). Top-ranked models were
further evaluated in molecular docking screens. The ability of each model to
identify ligands was assessed by screening active compounds from the
ChEMBL15 database (Gaulton et al., 2012) together with property-matched
decoys. Models that resulted in strong enrichment of known ligands were
used to derive side chain restraints, which were applied in subsequent rounds
of homology modeling. In the last step, five different models for each of the 5-
HT1B and 5-HT2B receptors with ergotamine docked to the orthosteric site
were submitted to the GPCR Dock 2013 assessment (http://gpcr.scripps.
edu/GPCRDock2013/) before the release of the crystal structures in the
PDB. The results for highest ranked complexes, as judged by the assessment
made by the organizers, were analyzed in this work.
PyMOL (http://www.pymol.org) was used to align the crystallographic
structures and homology models based on residues of the crystal structure
of the 5-HT1B receptor within 5 A˚ of ergotamine. The program mdpocket
(Schmidtke et al., 2010) was used with default parameters to calculate the
shape and volume of the binding cavity exploited by selective compounds.
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